Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Characteristics of the T2D subjects before treatment

From: Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial

Patient no.

Age

Gender

Marriage

History (year)

BMI

Fasting glucose

HbA1C (%)

C-peptide (ng/ml)*

Group A: Long-standing patients having normal β cell function with oral medications

1

60

M

Yes

13

30.42

10.39

8.6

2.93

2

38

M

Yes

8

20.9

8.39

9.6

0.89

3

53

M

Yes

4

28.72

9.3

7.9

2.07

4

41

F

Yes

4

26.81

8.2

7.8

1.88

5

29

M

Yes

2

26.78

6.2

7.5

1.67

6

43

F

Yes

2

27.55

10.83

8.7

1.93

7

61

M

Yes

8

30.81

6.53

7.4

1.6

8

68

F

Yes

6

21.2

6.21

8.4

0.97

9

40

M

Yes

6

25.31

15.95

12.3

0.8

10

36

M

Yes

1

25.14

11.59

10.2

1.03

11

54

F

Yes

13

28.28

11.95

8.9

0.91

12

55

F

Yes

14

25.04

8.27

9.7

0.91

13

57

M

Yes

1

26.4

6.95

7.5

1.41

14

54

M

Yes

15

32.35

7.6

7.9

1.5

15

45

F

Yes

1

25

9.46

8.4

1.89

16

58

F

Yes

10

22.91

8.97

9.7

1.08

17

57

F

Yes

14

23.88

7.38

7.4

1.07

18

64

M

Yes

13

32.81

8.3

8.4

2.09

Mean

50

  

7.5

26.68

9.03

8.68

1.48

(SD)

(11)

  

(5)

(3.46)

(2.44)

(1.25)

(0.58)

Group B: Long-standing patients having normal β cell function with insulin injection

19

52

M

Yes

12

28.12

10.63

9.4

1.08

20

44

F

Yes

9

24.2

10.64

8.1

0.96

21

60

F

Yes

12

23.23

11.55

10.0

1.13

22

56

M

Yes

11

28.37

12.19

7.5

1.19

23

46

M

Yes

5

29.05

7.62

7.8

1.61

24

44

M

Yes

2

31.35

10.99

8.5

1.96

25

40

M

Yes

4

24.46

9.1

7.4

1.29

26

61

F

Yes

13

30.47

11.03

8.8

1.53

27

64

F

Yes

2

27.06

8.63

8.3

1.64

28

39

M

Yes

11

28.09

10.94

9.8

1.84

29

47

M

Yes

7

26.45

7.27

7.9

1.33

Mean

50

  

8

27.35

10.05

8.5

1.41

(SD)

(9)

  

(4)

(2.59)

(1.63)

(0.9)

(0.32)

Group C: Long-standing patients having impaired β cell function with insulin injection

30

66

F

Yes

18

22.48

10.71

8.3

0.39

31

39

M

Yes

3

19.83

8.0

13.2

0.45

32

55

F

Yes

24

22.27

6.77

7.3

0.16

33

54

M

Yes

15

25.69

8.56

8.5

0.59

34

49

F

Yes

15

24.22

10.15

9.6

0.17

35

54

M

Yes

11

27.72

8.02

8.9

0.56

36

47

M

Yes

15

24.28

9.18

11.1

0.19

Mean

52

  

14

23.78

8.77

9.56

0.36

(SD)

(8)

  

(6)

(2.56)

(1.36)

(1.99)

(0.19)

  1. * The levels of 0.6 to approximately 3.4 ng/ml are the normal ranges for Chinese fasting C-peptide by radioimmunoassay (RIA). To convert C-peptide value to nmol/L, multiply the ng/ml by 0.331.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us